CEL-SCI Corporation Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- CEL-SCI Corporation's total funding is $24.4M.
- CEL-SCI Corporation has 26 Employees.
- CEL-SCI Corporation currently has 1 job openings.
What Is CEL-SCI Corporation?
CEL-SCI\'s story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, lack of funding, and a lengthy clinical trial process associated with the development of its investigational therapy for advanced primary head and neck cancer, CEL-SCI is finally approaching the end game! Our lead investigational immunotherapy, Multikine® (Leukocyte Interleukin, Injection), has been tested in Phase I and II clinical trials, and is now enrolling patients for a global Phase III trial. Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.keywords:Biotechnology